TY - JOUR
T1 - Lymphoma occurring during pregnancy
T2 - Antenatal therapy, complications, and maternal survival in a multicenter analysis
AU - Evens, Andrew M.
AU - Advani, Ranjana
AU - Press, Oliver W.
AU - Lossos, Izidore S.
AU - Vose, Julie M.
AU - Hernandez-Ilizaliturri, Francisco J.
AU - Robinson, Barrett K.
AU - Otis, Stavroula
AU - Dagan, Liat Nadav
AU - Abdallah, Ramsey
AU - Kroll-Desrosiers, Aimee
AU - Yarber, Jessica L.
AU - Sandoval, Jose
AU - Foyil, Kelley
AU - Parker, Linda M.
AU - Gordon, Leo I.
AU - Blum, Kristie A.
AU - Flowers, Christopher R.
AU - Leonard, John P.
AU - Habermann, Thomas M.
AU - Bartlett, Nancy L.
N1 - Publisher Copyright:
© 2013 by American Society of Clinical Oncology.
PY - 2013/11/10
Y1 - 2013/11/10
N2 - Purpose: Lymphoma is the fourth most frequent cancer in pregnancy; however, current clinical practice is based largely on small series and case reports. Patients and Methods: In a multicenter retrospective analysis, we examined treatment, complications, and outcomes for Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) occurring during pregnancy. Results: Among 90 patients (NHL, n = 50; HL, n = 40), median age was 30 years (range, 18 to 44 years) and median diagnosis occurred at 24 weeks gestation. Of patients with NHL, 52% had advanced-stage versus 25% of patients with HL (P = .01). Pregnancy was terminated in six patients. Among the other 84 patients, 28 (33%) had therapy deferred to postpartum; these patients were diagnosed at a median 30 weeks gestation. This compared with 56 patients (67%) who received antenatal therapy with median lymphoma diagnosis at 21 weeks (P < .001); 89% of these patients received combination chemotherapy. The most common preterm complication was induction of labor (33%). Gestation went to full term in 56% of patients with delivery occurring at a median of 37 weeks. There were no differences in maternal complications, perinatal events, or median infant birth weight based on deferred versus antenatal therapy. At 41 months, 3-year progression-free survival (PFS) and overall survival (OS) for NHL were 53% and 82%, respectively, and 85% and 97%, respectively, for HL. On univariate analysis for NHL, radiotherapy predicted inferior PFS, and increased lactate dehydrogenase and poor Eastern Cooperative Oncology Group performance status (ECOG PS) portended worse OS. For HL patients, nulliparous status and "B" symptoms predicted inferior PFS. Conclusion: Standard (non-antimetabolite) combination chemotherapy administered past the first trimester, as early as 13 weeks gestation, was associated with few complications and expected maternal survival with lymphoma occurring during pregnancy.
AB - Purpose: Lymphoma is the fourth most frequent cancer in pregnancy; however, current clinical practice is based largely on small series and case reports. Patients and Methods: In a multicenter retrospective analysis, we examined treatment, complications, and outcomes for Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) occurring during pregnancy. Results: Among 90 patients (NHL, n = 50; HL, n = 40), median age was 30 years (range, 18 to 44 years) and median diagnosis occurred at 24 weeks gestation. Of patients with NHL, 52% had advanced-stage versus 25% of patients with HL (P = .01). Pregnancy was terminated in six patients. Among the other 84 patients, 28 (33%) had therapy deferred to postpartum; these patients were diagnosed at a median 30 weeks gestation. This compared with 56 patients (67%) who received antenatal therapy with median lymphoma diagnosis at 21 weeks (P < .001); 89% of these patients received combination chemotherapy. The most common preterm complication was induction of labor (33%). Gestation went to full term in 56% of patients with delivery occurring at a median of 37 weeks. There were no differences in maternal complications, perinatal events, or median infant birth weight based on deferred versus antenatal therapy. At 41 months, 3-year progression-free survival (PFS) and overall survival (OS) for NHL were 53% and 82%, respectively, and 85% and 97%, respectively, for HL. On univariate analysis for NHL, radiotherapy predicted inferior PFS, and increased lactate dehydrogenase and poor Eastern Cooperative Oncology Group performance status (ECOG PS) portended worse OS. For HL patients, nulliparous status and "B" symptoms predicted inferior PFS. Conclusion: Standard (non-antimetabolite) combination chemotherapy administered past the first trimester, as early as 13 weeks gestation, was associated with few complications and expected maternal survival with lymphoma occurring during pregnancy.
UR - http://www.scopus.com/inward/record.url?scp=84891950541&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891950541&partnerID=8YFLogxK
U2 - 10.1200/JCO.2013.49.8220
DO - 10.1200/JCO.2013.49.8220
M3 - Article
C2 - 24043736
AN - SCOPUS:84891950541
SN - 0732-183X
VL - 31
SP - 4132
EP - 4139
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 32
ER -